Sales and distribution alliance with Phenocell, France: iPS cell-derived myeloid cell products (iMylc) will be launched in Europe.

Phenocell produces various somatic cells such as skin and retina from iPS cells and sells them worldwide. Phenocell has never handled a blood cell product line, and the partnership was formed because of the possibility of developing collaborative products with us. The company has started to provide iMylc cells (iPS derived myeloid lineage cells) and cMylc cells (coronavirus optimized myeloid lineage cells) for research on COVID-19 in France and Europe today.

For more information（PDF）→